Adaptimmune Therapeutics plc
ADAP
$0.2663
-$0.0576-17.78%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -74.22M | -17.62M | 69.52M | -48.50M | -47.92M |
| Total Depreciation and Amortization | 2.84M | 2.82M | 2.74M | 2.83M | 2.87M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.63M | 5.88M | 2.49M | 3.37M | 2.09M |
| Change in Net Operating Assets | 25.55M | -45.53M | -27.35M | 10.36M | 28.28M |
| Cash from Operations | -34.20M | -54.45M | 47.40M | -31.95M | -14.68M |
| Capital Expenditure | -219.00K | -143.00K | -422.00K | -102.00K | -827.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.39M | -65.88M | -321.00K | -256.00K | 69.02M |
| Cash from Investing | 8.17M | -66.02M | -743.00K | -358.00K | 68.20M |
| Total Debt Issued | 0.00 | 25.00M | 24.50M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.00K | 1.00K | 12.00K | 29.24M | 74.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.00K | 25.00M | 24.51M | 29.24M | 74.00K |
| Foreign Exchange rate Adjustments | -180.00K | 214.00K | -20.00K | -416.00K | 350.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.22M | -95.25M | 71.15M | -3.49M | 53.95M |
